Viral infectious diseases have caused millions of deaths worldwide. Antiviral agents are critical for controlling these infections; however, an open-access database dedicated specifically to antiviral agents remains unavailable. Here, we present AntiviralDB (https://www.antiviraldb.com/), an expert-curated resource that compiles both approved and experimental antiviral agents with laboratory-confirmed in vitro activity against a broad spectrum of human viruses. These include the human immunodeficiency virus, coronaviruses, hepatitis viruses, influenza virus, respiratory syncytial virus, herpes simplex virus, varicella-zoster virus, human cytomegalovirus, human papillomavirus, dengue virus, Zika virus, Ebola virus, mpox virus, norovirus, chikungunya virus, and 16 other common or life-threatening pathogens. Each antiviral agent in the database is annotated with key information, including its molecular target, in vitro antiviral activity (IC50, EC50, and CC50 across specific viral strains and cell lines), mechanism of action, and relevant pharmacokinetic and pharmacodynamic parameters. AntiviralDB also provides clinical efficacy and safety data derived from randomized clinical trials. Unlike existing drug databases, AntiviralDB offers two distinctive features: (i) standardized laboratory protocols for antiviral drug screening under appropriate biosafety conditions and (ii) clinical guidelines for the therapeutic use of antiviral agents against viral infections. By serving as a comprehensive repository of antiviral agents and their clinical applications, AntiviralDB aims to advance antiviral drug discovery and support the effective clinical management of viral infectious diseases.